Cytos Biotechnology AG

DGAP-News: Cytos Biotechnology Ltd announces financing transaction

EQS Group-News: Cytos Biotechnology AG / Key word(s): Capital Increase
Cytos Biotechnology Ltd announces financing transaction

10.10.2013 / 07:00

---------------------------------------------------------------------

This media release and the information contained herein is not being issued
in and may not be distributed directly or indirectly in certain countries,
including the United States, Canada, Australia, Hong Kong, Japan, New
Zealand, Singapore, South Africa or any other jurisdiction where it might
be unlawful to do so. This media release does not constitute an offer for
the sale of securities.

Cytos Biotechnology plans financing of up to CHF 17.6 million

CHF 9 million of proposed capital increase already firmly committed by
existing investors

Schlieren (Zurich), Switzerland, October 10, 2013 - Cytos Biotechnology Ltd
(SIX:CYTN) ('Cytos' or the 'Company') today announced a planned financing
transaction that will raise up to CHF 17.6 million by selling up to 6.3
million shares in a rights offering. The group of institutional and
strategic shareholders that invested in the Company in 2012, namely
Abingworth, venBio, Aisling and Amgen, will increase their investment by
CHF 9 million as part of the rights offering. The Company's board of
directors intends to make available to new investors any shares that are
not subscribed by the current shareholders in the rights offering.

The cash proceeds will ensure that Cytos remains well capitalized to
further advance the development of its lead program CYT003.

Dr. Christian Itin, Chairman and CEO of Cytos, said: 'We appreciate the
continued support of our major shareholders. The currently ongoing Phase 2b
clinical trial in patients with moderate to severe allergic asthma is
progressing as planned and we expect top line data to be available in the
second quarter of 2014 and the full study results becoming available in
late 2014.'

Further details of the planned shareholders' meeting

The proposal for an ordinary capital increase will be presented to the
shareholders for approval at an extraordinary shareholders' meeting to be
held on November 4, 2013. The Company's major shareholders who collectively
hold more than 50% of the outstanding share capital have committed to vote
in favor of the ordinary capital increase. At this shareholders' meeting,
the Company also plans to seek approval for the creation of additional
conditional and authorized capital of up to 3.15  million shares each, with
a nominal value of CHF 0.10 per share. The invitation and agenda for this
meeting will be sent to shareholders shortly.

For further information, please contact:

Cytos Biotechnology Ltd
Christian Itin, PhD
Chairman and Chief Executive Officer
Tel: +41 44 733 47 70
e-mail: christian.itin@cytos.com

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company focused on the development of
targeted immuno-therapies. The Company's lead product candidate CYT003 is a
novel, first-in-class, immune modulator in Phase 2 clinical development as
a potential new treatment for asthma.

CYT003 has a novel mechanism of action that inhibits the immune response
that causes asthma, and may therefore be beneficial for the control of
asthma. In a successfully completed Phase 2a study, CYT003 was shown to
maintain asthma control and lung function in patients with persistent
allergic asthma, despite withdrawal of standard therapy with inhaled
corticosteroids. CYT003 has been shown to have a good safety and
tolerability profile in more than 450 individuals receiving the active
agent so far.

Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of
Technology (ETH) in Zurich. It is located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the
SIX Swiss Exchange Ltd under the symbol CYTN.

www.cytos.com

Disclaimer

This document does neither constitute an offer to buy or to subscribe for
securities of Cytos Biotechnology Ltd nor a prospectus within the meaning
of applicable Swiss law. Investors should make their decision to buy or to
subscribe to securities of Cytos Biotechnology Ltd solely based on the
official offering and listing prospectus which will be published by Cytos
Biotechnology Ltd. Investors are furthermore advised to consult their bank
or financial adviser before making any investment decision. This document
does not constitute a prospectus pursuant to article 652a or 1156 of the
Swiss Code of Obligations or article 27 et seqq. of the listing rules of
the SIX Swiss Exchange Ltd. A decision to invest in securities of Cytos
Biotechnology Ltd should be based exclusively on the offering and listing
prospectus published by Cytos Biotechnology Ltd for such purpose.

The securities described herein are offered publicly in Switzerland only.
The information contained herein shall not constitute an offer to sell or
the solicitation of an offer to buy, in any jurisdiction in which such
offer or solicitation would be unlawful prior to registration, exemption
from registration or qualification under the securities laws of any
jurisdiction.

This document is not being issued in the United States of America, Canada,
Australia, Hong Kong, Japan, New Zealand, Singapore, South Africa or any
other jurisdiction where it might be unlawful to do so and should not be
distributed or otherwise transmitted into the United States, or any other
of the aforementioned jurisdictions, or to U.S. persons (as defined in the
U.S. Securities Act of 1933, as amended) or publications with a general
circulation in the United States or any other of the aforementioned
jurisdictions. This document does not constitute an offer or invitation to
subscribe for or to purchase any securities in the United States of America
or any other jurisdiction. Securities may not be offered or sold in the
United States of America absent registration or an exemption from
registration under the U.S. Securities Act of 1933.

The information contained herein does not constitute an offer of securities
to the public in the United Kingdom. No prospectus offering securities to
the public will be published in the United Kingdom. This document is only
being distributed to and is only directed at (i) persons who are outside
the United Kingdom or (ii) to investment professionals falling within
article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the Order) or (iii) high net worth entities, and

other persons to whom it may lawfully be communicated, falling within
article 49(2)(a) to (d) of the Order (all such persons together being
referred to as 'relevant persons'). The securities are only available to,
and any invitation, offer or agreement to subscribe, purchase or otherwise
acquire such securities will be engaged in only with, relevant persons. Any
person who is not a relevant person should not act or rely on this document
or any of its contents.

Any offer of securities to the public that may be deemed to be made
pursuant to this communication in any Member State of the European Economic
Area (EEA) that has implemented Directive 2003/71/EC (together with the
2010 PD Amending Directive 2010/73/EU, including any applicable
implementing measures in any Member State, the 'Prospectus Directive') is
only addressed to 'qualified investors' within the meaning of the
Prospectus Directive in that Member State.

Forward Looking Statements

This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider
statements that include the words 'committed', 'could', 'will', 'plans',
'enable', 'expected', 'proposed', 'intends', 'planned,' or the negative of
those words or other similar words to be uncertain and forward-looking.
Factors that may cause actual results to differ materially from any future
results expressed or implied by any forward-looking statements include
scientific, business, economic and financial factors, including that CYT003
may not demonstrate safety or efficacy in clinical trials, that there may
be delays in development or that CYT003 may not receive marketing approval,
and that the Company relies on outside financing to meet capital
requirements, which may not be available under acceptable terms or at all.
Against the background of these uncertainties, readers should not rely on
forward-looking statements. The Company assumes no responsibility for
updating forward-looking statements or adapting them to future events or
developments.


End of Corporate News

+++++
Additional features:

Document: http://n.equitystory.com/c/fncls.ssp?u=ITGGJMYXDT

Document title: Press_captial_increase_E

---------------------------------------------------------------------

10.10.2013 This Corporate News was distributed by EQS Schweiz AG.
www.eqs.com - news archive: http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.

---------------------------------------------------------------------


Language:    English
Company:     Cytos Biotechnology AG
             Wagistr. 25
             8952 Schlieren
             Switzerland
Phone:       +41 44 733 4747
Fax:         +41 44 733 4740
E-mail:   info@cytos.com
Internet: www.cytos.com
ISIN:        CH0011025217, CH0029060735
Valor:       -
Listed:      Freiverkehr in Berlin, München, Stuttgart; Frankfurt in
             Open Market ; SIX


End of News    EQS Group News-Service
---------------------------------------------------------------------
233991 10.10.2013
 



Weitere Meldungen: Cytos Biotechnology AG

Das könnte Sie auch interessieren: